| 42 -0.49 (-1.15%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 49.73 |
1-year : | 51.88 |
| Resists | First : | 42.58 |
Second : | 44.41 |
| Pivot price | 41.84  |
|||
| Supports | First : | 39.61 |
Second : | 32.95 |
| MAs | MA(5) : | 42.74 | MA(20) : | 41.63 |
| MA(100) : | 38.04 |
MA(250) : | 0 | |
| MACD | MACD : | 0.5 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 54.4 |
D(3) : | 65.8 |
| RSI | RSI(14): 53.9 |
|||
| 52-week | High : | 44.41 | Low : | 17.81 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ KNSA ] has closed below upper band by 45.0%. Bollinger Bands are 24.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 42.67 - 42.92 | 42.92 - 43.11 |
| Low: | 41.04 - 41.38 | 41.38 - 41.63 |
| Close: | 41.55 - 42.06 | 42.06 - 42.43 |
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
Wed, 24 Dec 2025
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Tue, 23 Dec 2025
How Investors Are Reacting To Kiniksa (KNSA) KPL-387 Progress And A Fresh Analyst Buy Rating - simplywall.st
Mon, 22 Dec 2025
Why Analysts Favor Kiniksa Pharmaceuticals (KNSA) - Yahoo Finance
Sun, 21 Dec 2025
Responsive Playbooks and the KNSA Inflection - Stock Traders Daily
Fri, 19 Dec 2025
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 52-Week High - Time to Buy? - MarketBeat
Fri, 19 Dec 2025
Kiniksa Pharmaceuticals stock hits all-time high at 42.99 USD By Investing.com - Investing.com Nigeria
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 45 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 91.9 (%) |
| Shares Short | 2,800 (K) |
| Shares Short P.Month | 2,830 (K) |
| EPS | 0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.09 |
| Profit Margin | 6 % |
| Operating Margin | 13.2 % |
| Return on Assets (ttm) | 3.7 % |
| Return on Equity (ttm) | 7.3 % |
| Qtrly Rev. Growth | 61.2 % |
| Gross Profit (p.s.) | 6.98 |
| Sales Per Share | 13.24 |
| EBITDA (p.s.) | 0.87 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 103 (M) |
| Levered Free Cash Flow | 50 (M) |
| PE Ratio | 93.33 |
| PEG Ratio | 0 |
| Price to Book value | 5.91 |
| Price to Sales | 3.17 |
| Price to Cash Flow | 18.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|